Data from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

Autor: Kent J. Weinhold, Xiaofei Wang, Jared D. Christensen, Shannon J. McCall, Frank Dunphy, Frances McSherry, Thomas A. D'Amico, David Harpole, Betty Tong, Jeffrey Crawford, Jeffrey Clarke, Debra Shoemaker, Mark Berry, Robyn Osborne, Chelsae Dumbauld, Patrick Healy, Neal Ready, John S. Yi

Purpose: To determine the immunologic effects of neoadjuvant chemotherapy plus ipilimumab in early-stage non–small cell lung cancer (NSCLC) patients.Experimental Design: This is a single-arm chemotherapy plus phased ipilimumab phase II study of 24

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eacf4afffa0e122b9e3988128aab15a0
https://doi.org/10.1158/1078-0432.c.6525255.v1

Figure S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

Autor: Kent J. Weinhold, Xiaofei Wang, Jared D. Christensen, Shannon J. McCall, Frank Dunphy, Frances McSherry, Thomas A. D'Amico, David Harpole, Betty Tong, Jeffrey Crawford, Jeffrey Clarke, Debra Shoemaker, Mark Berry, Robyn Osborne, Chelsae Dumbauld, Patrick Healy, Neal Ready, John S. Yi

Spaghetti plots of MDSC and Tregs by visits; stratified by overall response.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0da162410e81a09579faebeba60157d9
https://doi.org/10.1158/1078-0432.22462914.v1

Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

Autor: Jeffrey M. Clarke, Kent J. Weinhold, David H. Harpole, Robyn Osborne, Mark F. Berry, Frances McSherry, Xiaofei Wang, Jeffrey Crawford, Jared D. Christensen, Chelsae Dumbauld, Thomas A. D'Amico, Neal Ready, Shannon J. McCall, Debra Shoemaker, Betty C. Tong, Frank Dunphy, Patrick Healy, John S. Yi

Publikováno v: Clinical Cancer Research. 23:7474-7482

Purpose: To determine the immunologic effects of neoadjuvant chemotherapy plus ipilimumab in early-stage non–small cell lung cancer (NSCLC) patients. Experimental Design: This is a single-arm chemotherapy plus phased ipilimumab phase II study of 24

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b619429b8b6c7303bede656d200e8f9
https://doi.org/10.1158/1078-0432.ccr-17-2005

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Autor: Tony Mok, Mark G. Kris, Frank Dunphy, Hui Zhang, Dong Wan Kim, Zelanna Goldberg, Sai-Hong Ignatius Ou, Makoto Nishio, Geoffrey R. Oxnard, Ian Taylor, Renato G. Martins, Joe O'Connell, Pasi A. Jänne, Cloud P. Paweletz

Publikováno v: The Lancet Oncology. 15:1433-1441

Patients with EGFR-mutant non-small-cell lung cancer generally have a progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase inhibitors gefitinib or erlotinib. However, resistance inevitably develops, and more effe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c681654383208ca13731f63529beddf
https://doi.org/10.1016/s1470-2045(14)70461-9

Head and Neck Cancers, Version 2.2014

Autor: Thomas V. McCaffrey, Maura L. Gillison, Anthony J. Cmelak, Ying J. Hitchcock, Jimmy J. Caudell, Gregory T. Wolf, Miranda Hughes, Ellie Maghami, Cristina P. Rodriguez, Harlan A. Pinto, Paul M. Busse, Bharat B. Mittal, David E. Schuller, John A. Ridge, Antonio Jimeno, David W. Eisele, Loren K. Mell, David G. Pfister, Sharon A. Spencer, David M. Brizel, Frank Dunphy, A. Dimitrios Colevas, Bruce H. Haughey, Merrill S. Kies, Jill Gilbert, William M. Lydiatt, Wesley L. Hicks, Nicole R. McMillian, Robert I. Haddad, Randal S. Weber, Barbara Burtness, Sandeep Samant, Frank Worden, Renato G. Martins, Sue S. Yom, Jatin P. Shah

Publikováno v: Memorial Sloan Kettering Cancer Center
Pfister, DG; Spencer, S; Brizel, DM; Burtness, B; Busse, PM; Caudell, JJ; et al.(2014). Head and neck cancers, version 2.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(10), 1454-1487. doi: 10.6004/jnccn.2014.0142. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/2mg8p2dv

Copyright © 2014 by the National Comprehensive Cancer Network. All rights reserved. This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers focuses on glottic laryngeal cancer, which is the m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3da43c9b81f201a7f0eafd3ef3032696
https://doi.org/10.6004/jnccn.2014.0142